Supportive care for women with gynecologic cancers

References

• Le T, Leis A, Pahwa P et al. Quality-of-life issues in patients with ovarian cancer and their caregivers: a review. Obstet. Gynecol. Surv.58(11), 749–758 (2003).
   PubMed Web of Science ®Google Scholar
• Monk BJ, Wenzel L. Palliative care and quality of life. In: Clinical Gynecologic Oncology (7th Edition). DiSaia PJ, Creasman WT (Eds). Elsevier, Inc., St Louis, MO, USA (2007).
   Google Scholar
• Aranda S, Yates P, Edwards H et al. Barriers to effective cancer pain management: a survey of Australian family caregivers. Eur. J. Cancer Care (Engl.)13(4), 336–343 (2004).
   PubMedGoogle Scholar
• Vaz AF, Pinto-Neto AM, Conde DM et al. Quality of life of women with gynecologic cancer: associated factors. Arch. Gynecol. Obstet.276(6), 583–589 (2007).
   PubMedGoogle Scholar
• Silver J, Mayer RS. Barriers to pain management in the rehabilitation of the surgical oncology patient. J. Surg. Oncol.95(5), 427–435 (2007).
   PubMedGoogle Scholar
• Burton AW, Fanciullo GJ, Beasley RD et al. Chronic pain in the cancer survivor: a new frontier. Pain Med.8(2), 189–198 (2007).
   PubMed Web of Science ®Google Scholar
• Goldberg GR, Morrison RS. Pain management in hospitalized cancer patients: a systematic review. J. Clin. Oncol.25(13), 1792–1801 (2007).
   PubMed Web of Science ®Google Scholar
• Bajwa ZH, Warfield CA. Overview of cancer pain. In: UpToDate. Rose BD (Ed.). UpToDate, Waltham, MA, USA (2007).
   Google Scholar
• Chang HM. Cancer pain management. Med. Clin. North Am.83(3), vii711–vii736 (1999).
   Google Scholar
• Vielhaber A, Portenoy RK. Advances in cancer pain management. Hematol. Oncol. Clin. North Am.16(3), 527–541 (2002).
   PubMed Web of Science ®Google Scholar
• Femia RA, Goyette RE. The science of megestrol acetate delivery: potential to improve outcomes in cachexia. BioDrugs19(3), 179–187 (2005).
   PubMed Web of Science ®Google Scholar
• Marín Caro MM, Laviano A, Pichard C. Impact of nutrition on quality of life during cancer. Curr. Opin. Clin. Nutr. Metab. Care10(4), 480–487 (2007).
   PubMedGoogle Scholar
• Santoso JT, Canada T, Latson B et al. Prognostic nutritional index in relation to hospital stay in women with gynecologic cancer. Obstet. Gynecol.95(6 Pt 1), 844–846 (2000).
   PubMed Web of Science ®Google Scholar
• Mateen F, Jatoi A. Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients. Clin. Nutr.25(5), 711–715 (2006).
   PubMedGoogle Scholar
• Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia–cachexia syndrome. Cochrane Database Syst. Rev.(2) 18, CD004310 (2005).
   Google Scholar
• Kropsky B, Shi Y, Cherniack EP. Incidence of deep-venous thrombosis in nursing home residents using megestrol acetate. J. Am. Med. Dir. Assoc.4(5), 255–256 (2003).
   PubMedGoogle Scholar
• Brown D, Roberts JA, Elkins TE et al. Hard choices: the gynecologic cancer patient’s end-of-life preferences. Gynecol. Oncol.55(3 Pt 1), 355–362 (1994).
   PubMedGoogle Scholar
• Bozzetti F, Cozzaglio L, Biganzoli E et al. Quality of life and length of survival in advanced cancer patients on home parenteral nutrition. Clin. Nutr.21(4), 281–288 (2002).
   PubMed Web of Science ®Google Scholar
• Brard L, Weitzen S, Strubel-Lagan SL et al. The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients. Gynecol. Oncol.103(1), 176–180 (2006).
   PubMedGoogle Scholar
• Ripamonti C. Management of dyspnea in advanced cancer patients. Support. Care Cancer7(4), 233–243 (1999).
   PubMedGoogle Scholar
• Easson AM, Bezjak A, Ross S et al. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites. Ann. Surg. Oncol.14(8), 2348–2357 (2007).
   PubMedGoogle Scholar
• Smith EM, Jayson GC. The current and future management of malignant ascites. Clin. Oncol.15(2), 59–72 (2003).
   PubMed Web of Science ®Google Scholar
• Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur. J. Cancer42(5), 589–597 (2006).
   PubMed Web of Science ®Google Scholar
• Burges A, Wimberger P, Kümper C et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a Phase I/II study. Clin. Cancer Res.13(13), 3899–3905 (2007).
   PubMed Web of Science ®Google Scholar
• Mangili G, Aletti G, Frigerio L et al. Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis. Int. J. Gynecol. Cancer15(5), 830–835 (2005).
   PubMedGoogle Scholar
• Krebs HB, Goplerud DR. Surgical management of bowel obstruction in advanced ovarian carcinoma. Obstet. Gynecol.61(3), 327–330 (1983).
   PubMed Web of Science ®Google Scholar
• Pothuri B, Meyer L, Gerardi M et al. Reoperation for palliation of recurrent malignant bowel obstruction in ovarian carcinoma. Gynecol. Oncol.95(1), 193–195 (2004).
   PubMedGoogle Scholar
• Bryan DN, Radbod R, Berek JS. An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer. Int. J. Gynecol. Cancer16(1), 125–134 (2006).
   PubMedGoogle Scholar
• Moretti R, Pizzi B, Colizza MT et al. Symptom management in a patient with end-stage ovarian cancer: case report. Eur. J. Gynaecol. Oncol.28(4), 325–327 (2007).
   PubMedGoogle Scholar
• Rodriguez AO, Wun T, Chew H et al. Venous thromboembolism in ovarian cancer. Gynecol. Oncol.105(3), 784–790 (2007).
   PubMed Web of Science ®Google Scholar
• Einstein MH, Pritts EA, Hartenbach EM. Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review. Gynecol. Oncol.105(3), 813–819 (2007).
   PubMed Web of Science ®Google Scholar
• Zell JA, Chang JC. Neoplastic fever: a neglected paraneoplastic syndrome. Support. Care Cancer13(11), 870–877 (2005).
   PubMedGoogle Scholar
• Slatkin N. Cancer-related pain and its pharmacologic management in the patient with bone metastasis. J. Support. Oncol.4(2 Suppl. 1), 15–21 (2006).
   PubMedGoogle Scholar
• Sun CC, Bodurka DC, Donato ML et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol. Oncol.87(1), 118–128 (2002).
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS. Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. J. Support. Oncol.5(2 Suppl. 1), 5–12 (2007).
   PubMedGoogle Scholar
• Schwartzberg LS. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy? Oncology21(8) 946–953; discussion 954, 959, 962 passim . (2007).
   PubMed Web of Science ®Google Scholar
• Tipton JM, McDaniel RW, Barbour L et al. Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy-induced nausea and vomiting. Clin. J. Oncol. Nurs.11(1), 69–78 (2007).
   PubMedGoogle Scholar
• Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J. Clin. Oncol.24(18), 2932–2947 (2006).
   PubMed Web of Science ®Google Scholar
• Slatkin NE. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J. Support. Oncol.5(5 Suppl. 3), 1–9 (2007).
   PubMedGoogle Scholar
• Tramèr MR, Carroll D, Campbell FA et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. Br. Med. J.323(7303), 16–21 (2001).
   PubMed Web of Science ®Google Scholar
• Smith GF, Toonen TR. Primary care of the patient with cancer. Am. Fam. Physician75(8), 1207–1214 (2007).
   PubMed Web of Science ®Google Scholar
• Donovan HS, Ward S. Representations of fatigue in women receiving chemotherapy for gynecologic cancers. Oncol. Nurs. Forum32(1), 113–116 (2005).
   PubMed Web of Science ®Google Scholar
• Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist9(Suppl. 5), 31–40 (2004).
   PubMed Web of Science ®Google Scholar
• Barrett-Lee P, Bokemeyer C, Gascón P et al. Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist10(9), 743–757 (2005).
   PubMed Web of Science ®Google Scholar
• Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist9(Suppl. 5), 31–40 (2004).
   PubMed Web of Science ®Google Scholar
• Vaupel P, Thews O, Mayer A et al. Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strahlenther. Onkol.178(12), 727–731 (2002).
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J. Clin. Oncol.20(19), 4083–4107 (2002).
   PubMed Web of Science ®Google Scholar
• Kurz CH, Marth CH, Windbichler G et al. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol. Oncol.65(3), 461–466 (1997).
   PubMedGoogle Scholar
• Heddens D, Alberts DS, Hannigan EV et al. Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment. Gynecol. Oncol.86(3), 239–243 (2002).
   PubMed Web of Science ®Google Scholar
• Hensley ML, Lebeau D, Leon LF et al. Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer. Gynecol. Oncol.81(3), 485–489 (2001).
   PubMedGoogle Scholar
• Cersosimo RJ, Jacobson DR. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia. Ann. Pharmacother.40(1), 58–65; quiz 169 (2006).
   PubMed Web of Science ®Google Scholar
• De Los Santos JF, Thomas GM. Anemia correction in malignancy management: threat or opportunity? Gynecol. Oncol.105(2), 517–529 (2007).
   PubMedGoogle Scholar
• Huang HQ, Brady MF, Cella D et al. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int. J. Gynecol. Cancer17(2), 387–393 (2007).
   PubMed Web of Science ®Google Scholar
• Pignata S, De Placido S, Biamonte R et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer6, 5 (2006).
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Bogliun G, Marzorati L et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann. Oncol.15(9), 1439–1442 (2004).
   PubMed Web of Science ®Google Scholar
• Vielhaber A, Portenoy RK. Advances in cancer pain management. Hematol. Oncol. Clin. North Am.16(3), 527–541 (2002).
   PubMed Web of Science ®Google Scholar
• Albers J, Chaudhry V, Cavaletti G et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst. Rev. (1) (2007).
   PubMedGoogle Scholar
• Hilpert F, Stähle A, Tomé O et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/ paclitaxel-based chemotherapy – a double-blind, placebo-controlled, randomized Phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group. Support. Care Cancer13(10), 797–805 (2005).
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Chroni E, Koutras A et al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support. Care Cancer14(11), 1134–1140 (2006).
   PubMed Web of Science ®Google Scholar
• Stead ML, Fallowfield L, Selby P et al. Psychosexual function and impact of gynaecological cancer. Baillière’s best practice & research. Clin. Obstet. Gynaecol.21(2), 309–320 (2007).
   PubMed Web of Science ®Google Scholar
• Brotto LA, Heiman JR, Goff B et al. A psychoeducational intervention for sexual dysfunction in women with gynecologic cancer. Arch. Sex. Behav. (2007) (Epub ahead of print)..
   PubMedGoogle Scholar
• Hopkins ML, Fung MF, Le T et al. Ovarian cancer patients and hormone replacement therapy: a systematic review. Gynecol. Oncol.92(3), 827–832 (2004).
   PubMed Web of Science ®Google Scholar
• Barakat RR, Bundy BN, Spirtos NM et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol.24(4), 587–592 (2006).
   PubMed Web of Science ®Google Scholar
• Ell K, Sanchez K, Vourlekis B et al. Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. J. Clin. Oncol.23(13), 3052–3060 (2005).
   PubMed Web of Science ®Google Scholar
• Fowler JM, Carpenter KM, Gupta P et al. The gynecologic oncology consult: symptom presentation and concurrent symptoms of depression and anxiety. Obstet. Gynecol.103(6), 1211–1217 (2004).
   PubMedGoogle Scholar
• Chan YM, Ngan HY, Yip PS et al. Psychosocial adjustment in gynecologic cancer survivors: a longitudinal study on risk factors for maladjustment. Gynecol. Oncol.80(3), 387–394 (2001).
   PubMed Web of Science ®Google Scholar
• Bodurka-Bevers D, Basen-Engquist K, Carmack CL et al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol. Oncol.78(3 Pt 1), 302–308 (2000).
   PubMed Web of Science ®Google Scholar
• Rodin G, Lloyd N, Katz M et al. The treatment of depression in cancer patients: a systematic review. Support. Care Cancer15(2), 123–136 (2007).
   PubMed Web of Science ®Google Scholar
• Rodin G, Lloyd N, Katz M et al. The treatment of depression in cancer patients: a systematic review. Support. Care Cancer15(2), 123–136 (2007).
   PubMed Web of Science ®Google Scholar
• Lutgendorf SK, Anderson B, Ullrich P et al. Quality of life and mood in women with gynecologic cancer: a one year prospective study. Cancer94(1), 131–140 (2002).
   PubMed Web of Science ®Google Scholar
• Beesley V, Janda M, Eakin E et al. Lymphedema after gynecological cancer treatment: prevalence, correlates, and supportive care needs. Cancer109(12), 2607–2614 (2007).
   PubMed Web of Science ®Google Scholar
• Kligman L, Wong RK, Johnston M et al. The treatment of lymphedema related to breast cancer: a systematic review and evidence summary. Support. Care Cancer12(6), 421–431 (2004).
   PubMedGoogle Scholar
• Modesitt SC, van Nagell JR. The impact of obesity on the incidence and treatment of gynecologic cancers: a review. Obstet. Gynecol. Surv.60(10), 683–692 (2005).
   PubMed Web of Science ®Google Scholar
• Ben-Ami I, Vaknin Z, Schneider D et al. Perioperative morbidity and mortality of gynecological oncologic surgery in elderly women. Int. J. Gynecol. Cancer16(1), 452–457 (2006).
   PubMedGoogle Scholar
• Gridelli C. Same old story? Do we need to modify our supportive care treatment of elderly cancer patients? Focus on antiemetics. Drugs Aging21(13), 825–832 (2004).
   PubMedGoogle Scholar
• Swisher EM, Cohn DE, Goff BA et al. Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol. Oncol.84(3), 363–367 (2002).
   PubMedGoogle Scholar
• von Gruenigen VE, Frasure HE, Jenison EL et al. Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy. Gynecol. Oncol.103(1), 120–126 (2006).
   PubMedGoogle Scholar
• Thorsen L, Skovlund E, Strømme SB et al. Effectiveness of physical activity on cardiorespiratory fitness and health-related quality of life in young and middle-aged cancer patients shortly after chemotherapy. J. Clin. Oncol.23(10), 2378–2388 (2005).
   PubMed Web of Science ®Google Scholar
• Karvinen KH, Courneya KS, Campbell KL et al. Exercise preferences of endometrial cancer survivors: a population-based study. Cancer Nurs.29(4), 259–265 (2006).
   PubMed Web of Science ®Google Scholar
• Courneya KS, Karvinen KH, Campbell KL et al. Associations among exercise, body weight, and quality of life in a population-based sample of endometrial cancer survivors. Gynecol. Oncol.97(2), 422–430 (2005).
   PubMedGoogle Scholar
• Miller BE, Pittman B, Strong C. Gynecologic cancer patients’ psychosocial needs and their views on the physician’s role in meeting those needs. Int. J. Gynecol. Cancer13(2), 111–119 (2003).
   PubMed Web of Science ®Google Scholar
• Hodgkinson K, Butow P, Fuchs A et al. Long-term survival from gynecologic cancer: psychosocial outcomes, supportive care needs and positive outcomes. Gynecol. Oncol.104(2), 381–389 (2007).
   PubMed Web of Science ®Google Scholar
• Wenzel LB, Huang HQ, Armstrong DK et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol.25(4), 437–443 (2007).
   PubMed Web of Science ®Google Scholar
• Wenzel L, Huang HQ, Monk BJ et al. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol.23(24), 5605–5612 (2005).
   PubMed Web of Science ®Google Scholar
• Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am. Fam. Physician74(8), 1347–1354 (2006).
   PubMed Web of Science ®Google Scholar
• Hosseinimehr SJ. Trends in the development of radioprotective agents. Drug Discov. Today12(19–20), 794–805 (2007).
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Chroni E, Koutras A et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology64(1), 26–31 (2005).
   PubMed Web of Science ®Google Scholar
• Wang J, Lu Z, Au JL. Protection against chemotherapy-induced alopecia. Pharm. Res.23(11), 2505–2514 (2006).
   PubMed Web of Science ®Google Scholar
• Hurria A, Somlo G, Ahles T. Renaming “chemobrain”. Cancer Invest.25(6), 373–377 (2007).
   PubMed Web of Science ®Google Scholar